Halopropane
 | |
| Clinical data | |
|---|---|
| Trade names | Tebron |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C3H3BrF4 |
| Molar mass | 194.955 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed.[1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane.[2][3][4]
See also
[edit]References
[edit]- ↑ Webster NR, Galley HF (22 August 2013). Landmark Papers in Anaesthesia. OUP Oxford. pp. 70–. ISBN 978-0-19-163319-5.
- ↑ Acta anaesthesiologica Belgica. Acta Medica Belgica. 1974.
- ↑ Klein SL (1993). A glossary of anesthesia and related terminology. Springer-Verlag. ISBN 978-0-387-97831-4.
- ↑ Catcott EJ, Smithcors JF (1973). Progress in canine practice. American Veterinary Publications.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |